Cost Effective Trileaflet BioPolymeric Heart Valve For India

描述：目前所有的人工心脏瓣膜都存在血液相容性和血栓栓塞性并发症的风险问题。印度的低成本Chitra机械心脏瓣膜需要强大的终身抗凝治疗，是目前印度唯一满足以年轻人为主的心脏瓣膜患者的瓣膜。因此，大多数印度患者不得不面对终身抗凝治疗的风险。生物心脏瓣膜要么过于昂贵，要么患者不喜欢再次手术的前景，因为这些瓣膜的耐用性相对较差，而且印度医院的感染率很高。此外，还存在与使用猪或牛组织有关的个人宗教偏好引起的关切。由于患者年龄和更严重的耐久性问题，美国最近发展的微创技术对印度没有吸引力。目前需要的是一种低成本、无组织、生物相容的三叶心脏瓣膜。聚合心脏瓣膜有望带来最好的机械瓣膜和生物人工心脏瓣膜。我们的实验室开发了一种新型的生物材料Bio-Poly，它涉及到在分子水平上与透明质酸(HA，一种自然产生的多糖)互锁的聚合物材料的工程，以制造具有工程合成聚合物的耐久性的高度亲水性、血液和生物相容的聚合物小叶。初步工作表明，与普通聚合物薄膜相比，Bio-Poly薄膜具有显著的血液相容性。此外，我们已经证明了将Bio-Poly瓣叶组装成具有良好血流动力学特性的植入型三叶瓣膜假体的可行性。目前的R03研究旨在测试和优化Bio-Poly瓣膜作为下一代低成本和优越的心脏瓣膜。我们的中心假设是：Bio-Poly是一种仅使用阿司匹林抗凝方案的三叶心脏瓣膜置换术的有效和低成本的生物材料。这在三个目标上得到了检验。目的1重点研究新瓣膜的血流动力学和耐久性测试，同时优化瓣叶吸收特性。目标2专注于优化材料制造工艺，以最大限度地提高这些阀门的血液相容性。目标3专注于启动动物试验，以验证体内血液相容性和钙化，并为其在印度的商业化奠定基础。这些研究是由美国和印度团队与我们的商业合作伙伴TTK Healthcare合作进行的。TTK Healthcare是印度一家主要的阀门制造商，致力于将我们的低成本技术商业化，以迎合印度市场。我们的方法是创新的，使用HA作为试剂，为原本不相容的耐用疏水聚合物小叶带来血液相容性，这些小叶具有以低成本和高设计容差进行大规模生产的潜力。

DESCRIPTION: All present day prosthetic heart valves have issues regarding blood compatibility and risk of thromboembolic complications. India's low cost Chitra mechanical heart valve that requires strong life-long anti-coagulation therapy is the only valve that presently caters to the predominantly young heart valve patient in India. Therefore, most Indian patients have no choice but to face the risks of life long anti-coagulation therapy. Bio-prosthetic heart valves are either too expensive or the patients do not prefer the prospect of re-operation secondary to relatively poor durability of these valves and high rate of infection in Indian hospitals. Further there exists concern arising from personal religious preference related to use of porcine or bovine tissue. Recent development of minimally invasive technology in the United States is not as attractive to India due to the patient age, and more severe durability concerns. What is needed is a low-cost non-tissue based biocompatible tri-leaflet heart valve. Polymeric heart valves have the promise to bring the best of mechanical valves and bio-prosthetic heart valves. Our lab has developed a novel biomaterial, Bio-Poly, which involves the engineering of polymeric materials that are, at a molecular level, interlocked with hyaluronan (HA, a naturally occurring polysaccharide) to make highly hydrophilic hemo- and bio-compatible polymer leaflets with the durability of engineered synthetic polymers. Preliminary work has shown that Bio-Poly leaflets have a remarkably hemo-compatible compared to plain polymer leaflets. Further, we have already demonstrated the feasibility of assembling Bio-Poly leaflets into implantable tri-leaflet valve prosthesis with excellent hemodynamic characteristics. The present R03 study aims to test and optimize Bio-Poly valves as the next generation low-cost and superior heart valve. Our central hypothesis is: that Bio-poly is an effective and low-cost biomaterial for tri-leaflet heart valve prosthesis with aspirin regimen anticoagulation only. This is tested in three aims. Aim 1 focuses on hemodynamic and durability testing of the new valves while optimizing leaflet cooptation characteristics. Aim 2 focuses on optimizing the materials manufacturing process to maximize hemo-compatibility of these valves. Aim 3 focuses on commencing animal trials to validate hemocompatibility and calcification in vivo and lay the groundwork for commercialization in India. These studies are jointly conducted by the US and Indian teams in collaboration with our commercial partner, TTK Healthcare. TTK Healthcare is a major valve manufacturer in India that is committed to commercialize our low-cost technology to cater to the Indian market. Our approach is innovative with the use of HA, as the agent that brings hemo-compatibility to otherwise non-compatible, durable hydrophobic polymer leaflets that have the potential for scaling towards mass production at low-cost and high design tolerance.